Issues Regarding Antiretroviral Treatment for Patients With HIV-1 Infection

JAMA: The Journal of the American Medical Association

Volumn 278, Issue 15, 1997, Pages 1234-1235

  Macher, Abe M ^a   Goosby, Eric P ^b  

^a HEALTH RESOURCES AND SERVICES ADMINISTRATION   (United States)

^b VA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

DRUG COMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRACTICE GUIDELINE; PRISON; VIRUS LOAD; ADULT; CHILD; INFANT; PRESCHOOL CHILD; DISEASE TRANSMISSION; FEMALE; PREGNANCY; PREGNANCY COMPLICATION;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; PRACTICE GUIDELINES; PRISONS; VIRAL LOAD; ADULT; CHILD; CHILD, PRESCHOOL; INFANT; DISEASE TRANSMISSION, VERTICAL; FEMALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 0031572423     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1997.03550150038028     Document Type: Letter

References (6)

1. National Commission on Acquired Immune Deficiency Syndrome. Report-HIV Disease in Correctional Facilities. Washington, DC. March 1991.
2. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1997;277:1962-1969.
3. Quinn T. Acute primary HIV infection. JAMA. 1997;278:58-62.
4. Niu M, Stein D, Schnittman S. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis. 1993;168:1490-1501.
5. Pedersen C, Lindhardt B, Jensent B, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ. 1989;299:154-157.
6. Perrin TH, Markowitz M, Calandra G, et al. An open treatment study of acute HIV infection with zidovudine, thamivudine and indinavir sulfate. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections; January 23, 1996;Washington, DC.